Annabelle G Hayes, Venessa H M Tsang, Ann I McCormack, Roderick J Clifton-Bligh, Alexander M Menzies
{"title":"Immunotherapy mediated pituitary toxicity: current knowledge and priorities for care.","authors":"Annabelle G Hayes, Venessa H M Tsang, Ann I McCormack, Roderick J Clifton-Bligh, Alexander M Menzies","doi":"10.1210/endrev/bnag041","DOIUrl":"https://doi.org/10.1210/endrev/bnag041","url":null,"abstract":"<p><p>Immune checkpoint inhibitor related pituitary toxicity (pituitary irAE) remains a relatively common complication of treatment which has transformed prognosis in several solid organ malignancies. While it may present with clear and clinically significant adrenal insufficiency, diagnostic uncertainty can remain due its potentially subtle clinical phenotype and symptom overlap with other treatment related effects. Currently pituitary irAE lacks a validated biomarker or single unifying pathophysiological model. This review aims to outline what is known regarding pathogenesis, presentation, biomarkers and long-term outcomes of pituitary irAE to inform future directions and priorities for care and research. Emerging data suggest multiple plausible immune pathways, including activation of pre-existing autoimmunity, direct checkpoint-mediated pituitary toxicity, paraneoplastic immune responses and cytokine-driven injury, but these mechanisms likely vary between patients. This review also explores current and future clinical priorities for hormone replacement, patient education and ongoing endocrine follow-up. As survival improves for patients receiving immune checkpoint inhibitors, improved phenotyping, biomarker development and long-term outcomes research will be essential to refine diagnosis, prognostication and survivorship care.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Review of Preclinical and Human Data.","authors":"Elsa W Braunstein, Glenn D Braunstein","doi":"10.1210/endrev/bnag044","DOIUrl":"https://doi.org/10.1210/endrev/bnag044","url":null,"abstract":"<p><p>Preclinical rodent studies showing a dose-dependent increase in thyroid C-cell hyperplasia and neoplasia with Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs), led the United States Federal Drug Administration to require a boxed warning contraindicating GLP-1RAs for patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome. However, neither primate oncogenicity studies nor patient clinical trials showed C-cell stimulation, calling into question the relevance of rodent models to humans. Indeed, rodents have a high rate of spontaneous thyroid C-cell tumors, a higher number of thyroid C-cells and GLP-1 receptors and use a different pathway from humans in MTC oncogenesis. Although, the majority of meta-analyses of randomized clinical trials and cohort studies using administrative, electronic medical record and/or registry databases report no clear association between GLP-1RA use and thyroid cancer development, pharmacovigilance database studies do demonstrate a positive relationship; however, this association can only be inferred as a possible signal rather than causation and is likely due to notoriety or reporting bias. Additionally, analysis of the overall trends of thyroid cancer incidence in the U.S. since the release of GLP-1RAs for patient use in 2005 show an early increase, probably due to overdiagnosis of papillary carcinoma (PTC); however, the relative proportion of MTC has actually decreased. Because the preponderance of data does not support a causative relationship between GLP-1RA use and MTC (or PTC), we conclude that the need for the boxed warning about the risk of C-cell neoplasia is no longer necessary.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristian A Carvajal, Alejandra Tapia-Castillo, Thomas Uslar, Anand Vaidya, Jorge A Pérez, René Baudrand, Carlos E Fardella
{"title":"Non-Classical Apparent Mineralocorticoid Excess Syndrome: Current Evidence and Future Challenges.","authors":"Cristian A Carvajal, Alejandra Tapia-Castillo, Thomas Uslar, Anand Vaidya, Jorge A Pérez, René Baudrand, Carlos E Fardella","doi":"10.1210/endrev/bnag040","DOIUrl":"https://doi.org/10.1210/endrev/bnag040","url":null,"abstract":"<p><p>Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in whom the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classical apparent mineralocorticoid excess (NC-AME), defined by partial insufficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), represents a prevalent and underrecognized cause of cortisol-mediated mineralocorticoid receptor overactivation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This Scientific Statement addresses that gap. The panel formally defines NC-AME as a syndrome of partial 11β-HSD2 insufficiency occurring in the absence of biallelic HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The Statement consolidates evidence across three mechanistic domains, genetic and epigenetic dysregulation of HSD11B2, endogenous and exogenous enzyme inhibition, and patient-specific alterations (i.e. age, sex, renal function), and proposes both a structured, an LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicola Marrano, Angela Cappello, Giuseppina Biondi, Carlo Ganini, Antonella Cormio, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio
{"title":"Overlapping roles of dysregulated glycolysis in the pathophysiology of diabetes and cancer.","authors":"Nicola Marrano, Angela Cappello, Giuseppina Biondi, Carlo Ganini, Antonella Cormio, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio","doi":"10.1210/endrev/bnag043","DOIUrl":"https://doi.org/10.1210/endrev/bnag043","url":null,"abstract":"<p><p>Emerging evidence highlights a strong association between type 2 diabetes (T2D) and increased cancer risk, with partially overlapping metabolic disruptions potentially driving both diseases. Chronic hyperglycemia, a hallmark of T2D, disrupts glycolytic flux and contributes to the accumulation of toxic intermediates, driving cellular damage and diabetic complications. Specifically, dysregulation of glycolytic enzymes diverts metabolites into harmful pathways, promoting oxidative and glycative stress across multiple cell types. Similar metabolic disturbances support cancer development and progression by fueling rapid tumor cell proliferation. This review explores the role of abnormal glycolysis as a potential mechanistic link between T2D and cancer, detailing shared enzymatic alterations and metabolic pathway shifts. Additionally, it discusses pharmacological therapeutic strategies targeting glycolysis-related abnormalities common to both diseases, emphasizing the need for balanced metabolic modulation.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Angelousi, Marina Tsoli, Krystallenia I Alexandraki, Gregory Kaltsas
{"title":"\"Paraneoplastic syndromes secondary to Νeuroendocrine Νeoplasms\".","authors":"Anna Angelousi, Marina Tsoli, Krystallenia I Alexandraki, Gregory Kaltsas","doi":"10.1210/endrev/bnag042","DOIUrl":"https://doi.org/10.1210/endrev/bnag042","url":null,"abstract":"<p><p>Paraneoplastic syndromes (PNS) represent uncommon but clinically significant manifestations of neuroendocrine neoplasms (NENs) arising from ectopic hormone secretion, aberrant peptide processing, cytokine-mediated effects, or immune-mediated mechanisms. Although NENs are intrinsically capable of producing bioactive substances leading to PNS, the true prevalence of PNS in NENs remains uncertain and is likely underestimated. Paraneoplastic manifestations may precede tumor diagnosis, represent the first indication of an otherwise occult neoplasm, or emerge during disease progression, thereby providing valuable diagnostic, prognostic, and therapeutic information. Endocrine PNS, including ectopic adrenocorticotrophic hormone secretion, carcinoid syndrome, paraneoplastic hypercalcemia, syndrome of inappropriate antidiuretic hormone secretion, hypoglycemia and ectopic acromegaly, account for the majority of cases, whereas neurological PNS are rarer and predominantly associated with high-grade neuroendocrine carcinomas (NECs). Recent advances in molecular biology have revealed the importance of neuroendocrine lineage plasticity, transcriptional dysregulation, epigenetic reprogramming, and abnormal prohormone processing in the pathogenesis of these syndromes. Concurrently, improvements in biochemical testing, functional imaging, liquid biopsy technologies, and molecular profiling have enhanced diagnostic accuracy and disease monitoring. Management requires a multidisciplinary approach combining syndrome-directed therapies with tumor-targeted interventions, including surgery, somatostatin analogs, peptide receptor radionuclide therapy, targeted agents, specific chemotherapy regimens and emerging immunotherapeutic strategies. Despite substantial progress, significant gaps remain regarding epidemiology, accurate biomarkers, prognostic significance, and optimal management. This review summarizes current knowledge on pathophysiology, clinical spectrum, diagnosis, prognostic implications, and treatment of PNS associated with gastroenteropancreatic and lung NENs, while highlighting future research priorities and unmet clinical needs.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149264383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P K Mustakin, Mansyur Arief, K Nurrahmi, Liong Boy Kurniawan, Ihza Makarim Amirul Reswara
{"title":"The Microbiome-Metabolokine-Adipokine Axis in Insulin Resistance: Adaptive and Maladaptive FGF21-GDF15 Signaling.","authors":"P K Mustakin, Mansyur Arief, K Nurrahmi, Liong Boy Kurniawan, Ihza Makarim Amirul Reswara","doi":"10.1210/endrev/bnag038","DOIUrl":"https://doi.org/10.1210/endrev/bnag038","url":null,"abstract":"<p><p>Insulin resistance emerges from disturbances in interorgan metabolic communication in which nutrient exposure, microbial metabolism, and host endocrine responses interact across multiple metabolic compartments. This state-of-the-art review proposes a revised Microbiome-Metabolokine-Adipokine (MMA) Axis as a focused framework linking gut microbial metabolic signals with enteroendocrine, hepatic, and adipose responses and the stress-responsive metabolokines fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15). Microbiome-derived and microbiome-modified signals, including short-chain fatty acids, bile acids, branched-chain amino acid-related metabolites, tryptophan-derived metabolites, and microbial inflammatory products, can influence intestinal receptor signaling, incretin secretion, hepatic nutrient sensing, adipose lipid buffering, and systemic insulin sensitivity. Within this network, FGF21 and GDF15 are positioned as distinct but complementary adaptive endocrine signals rather than components of a fixed sequential pathway: FGF21 predominantly coordinates responses to nutrient and metabolic stress, whereas GDF15 communicates broader cellular stress through GFRAL-RET-dependent regulation of nutrient intake and energy balance. Importantly, persistent elevation of either metabolokine during insulin-resistant states should not automatically be interpreted as endocrine resistance or maladaptation. We instead propose that progression toward insulin resistance reflects a context-dependent mismatch between increasing metabolic stress and the capacity of integrated endocrine responses to maintain metabolic flexibility and substrate homeostasis. Current evidence strongly supports individual microbiome-metabolite, enteroendocrine, hepatic, adipose, FGF21, and GDF15 signaling modules, but a direct causal microbiome-FGF21-GDF15 sequence has not been established in humans. The revised MMA Axis therefore provides a testable framework for defining how microbiome-derived metabolic signals interface with host endocrine adaptation during the development of insulin resistance.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":""},"PeriodicalIF":23.9,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Menopause-driven metabolomic shifts: unraveling cardiovascular disease risk in women","authors":"Cristina Molina-López,Marta Rojas-Torres,Angela Rubio,Inés Pineda-Torra","doi":"10.1210/endrev/bnag036","DOIUrl":"https://doi.org/10.1210/endrev/bnag036","url":null,"abstract":"Abstract Menopause marks the end of a woman's reproductive life, and the transition to this stage is accompanied by profound physiological and metabolic changes. These include alterations in lipoproteins and various metabolites, such as lipids, fatty acids, and amino acids, resulting in a more atherogenic profile and, in some cases, an increased risk in cardiovascular disease (CVD). CVD remains the leading cause of death among women, and lipid profiles change substantially in postmenopause, representing a key sex-specific risk factor. Thus, elucidating the metabolic pathways affected during menopause is crucial to reducing the burden of menopause-related conditions. However, the underlying molecular mechanisms of this increased metabolic burden remain incompletely understood. Recent advances in metabolomic technologies, including mass spectrometry (MS), nuclear magnetic resonance (NMR), and computational tools, have greatly improved our ability to characterize these metabolic shifts. This review summarizes current knowledge on the metabolic changes associated with menopause and their implications for CVD development.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":"45 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yoshi Tan, Michael J Stark, Vicki L Clifton, Michael D Wiese, Janna L Morrison, Kathryn L Gatford
{"title":"Glucocorticoids in pregnancy: a master-switch for fetal maturation.","authors":"Yoshi Tan, Michael J Stark, Vicki L Clifton, Michael D Wiese, Janna L Morrison, Kathryn L Gatford","doi":"10.1210/endrev/bnag015","DOIUrl":"10.1210/endrev/bnag015","url":null,"abstract":"<p><p>The prepartum surge in plasma glucocorticoids is a critical signal for fetal organ maturation, facilitating the transition from fetal reliance on the placenta for functions such as respiration, nutrition, and waste removal to newborn use of their own physiological systems. The fetal glucocorticoid surge is conserved across mammalian species, but mechanisms driving the surge differ. Preterm birth interrupts fetal maturation because babies are born before the rise in endogenous glucocorticoids occurs, placing the newborn at greater risk of morbidity and mortality. In particular, lung immaturity increases risk of short-term and long-term respiratory disease. Antenatal corticosteroids (ACS) are routinely administered to women at risk of preterm birth to mimic the missed maturational signal of elevated glucocorticoids. Consequently, ACS improve neonatal survival and respiratory outcomes. Clinical guidelines universally recommend ACS use, but recommended regimens, gestational age limits, and use in settings of preexisting maternal conditions vary. Importantly, preterm infants have variable responsiveness to ACS treatment, and do not benefit equally. While male fetal sex and fetal growth restriction may be associated with lower ACS responsiveness, there is limited understanding of underlying factors. Emerging evidence points to differential glucocorticoid receptor isoform expression and elevated pretreatment plasma cortisol concentrations as potential contributors to variable ACS response. Improved insight into underlying mechanisms is crucial for identifying responsive subgroups and optimizing ACS treatment beyond the current one-size-fits-all approach to enhance health outcomes for preterm infants.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":"666-701"},"PeriodicalIF":23.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13577750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Insulin/IGF signaling in islet biology and its therapeutic implications.","authors":"Hyunki Kim, Rohit N Kulkarni","doi":"10.1210/endrev/bnag014","DOIUrl":"10.1210/endrev/bnag014","url":null,"abstract":"<p><p>The islet of Langerhans (or pancreatic islet) is a unique endocrine organ that secretes multiple hormones that in turn orchestrate energy metabolism in humans. As in other metabolic organs, growth factor(s) regulate functional islet mass to maintain whole-body glucose homeostasis. Over the past decades, a large body of evidence has pointed to insulin and insulin-like growth factors (IGFs) as playing central roles in modulating diverse aspects of islet cell biology and a dysregulated insulin/IGF pathway has come to be recognized as a pathophysiological hallmark of type 2 diabetes. Several recent reports, especially focused on β-cells, highlight emerging aspects of insulin/IGF signaling, including a role for RNA modifications, transcriptional regulation by nuclear insulin and IGF-1 receptors, and the discovery of an insulin inhibitory receptor, inceptor. In this review, we summarize the functional roles of insulin/IGF signaling in regulating islet cell biology, the short- and long-term effects of insulin therapy in humans, and propose potential strategies to maximize the beneficial effects of insulin action in islets to counter diabetes.</p>","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":"637-665"},"PeriodicalIF":23.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to \"Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement\".","authors":"","doi":"10.1210/endrev/bnag031","DOIUrl":"10.1210/endrev/bnag031","url":null,"abstract":"","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":"704"},"PeriodicalIF":23.9,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}